Drug intelligence / Profile preview

phosphatidylcholine + piracetam

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Phosphatidylcholine + piracetam is a combination of two agents commonly used as nootropics to enhance cognitive function. Phosphatidylcholine (often derived from lecithin) is a major component of biological membranes and serves as a precursor for the neurotransmitter acetylcholine, which plays an essential role in memory and learning. Piracetam is a synthetic derivative of gamma-aminobutyric acid (GABA) and was the first compound classified as a nootropic; it is believed to modulate neuronal membrane fluidity, enhance neuroplasticity, improve cerebral blood flow, and facilitate cholinergic neurotransmission. The combination has been studied for its potential synergistic effects on cognition in conditions such as Alzheimer's disease and age-related memory impairment. While animal studies suggest that combining choline or phosphatidylcholine with piracetam may produce greater improvements in memory retention than either agent alone[2], clinical trials in humans have shown mixed results[1]. This combination is generally well tolerated.

Other names
lecithin + piracetamcholine + piracetam
02

Targets

AMPAR (AMPA receptor)GABAA (Gamma-aminobutyric acid receptor)

Beyond the preview

Go deeper on phosphatidylcholine + piracetam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on phosphatidylcholine + piracetam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call